# A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treat

Source: https://onco.cc/trials/nct03888105/  
OnCo record `nct03888105` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Odronextamab in hodgkin lymphoma and non-hodgkin lymphoma, run by Regeneron Pharmaceuticals, active and no longer recruiting.

## Summary

A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies is a phase 2 interventional study registered as NCT03888105 by Regeneron Pharmaceuticals, with 515 participants enrolled, started 2019-11-13 and due to reach its primary completion in 2026-06-17. Interventions recorded: Odronextamab. Conditions listed: B-cell Non-Hodgkin Lymphoma (B-NHL). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT03888105
- Phase: 2
- Setting: An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Sponsor: Regeneron Pharmaceuticals
- Enrolled: 515

## Sources

- ClinicalTrials.gov NCT03888105: https://clinicaltrials.gov/study/NCT03888105

## Connected records

- cancers: [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Odronextamab](https://onco.cc/drugs/odronextamab/)
- companies: [Regeneron](https://onco.cc/companies/regeneron/)

---
JSON: https://onco.cc/api/v1/entities/nct03888105.json